45.04
3.18%
-1.48
Pre-market:
48.00
2.96
+6.57%
Apogee Therapeutics Inc stock is traded at $45.04, with a volume of 334.24K.
It is down -3.18% in the last 24 hours and down -15.86% over the past month.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Its two programs are APG777 and APG808, which initially develop for treating AD and COPD, respectively.
See More
Previous Close:
$46.52
Open:
$46.4
24h Volume:
334.24K
Relative Volume:
0.85
Market Cap:
$2.62B
Revenue:
-
Net Income/Loss:
$-118.49M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
$-110.57M
1W Performance:
-14.68%
1M Performance:
-15.86%
6M Performance:
-14.08%
1Y Performance:
+149.94%
Apogee Therapeutics Inc Stock (APGE) Company Profile
Name
Apogee Therapeutics Inc
Sector
Industry
Phone
650-394-5230
Address
221 CRESCENT ST., WALTHAM
Compare APGE with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
APGE | 45.04 | 2.62B | 0 | -118.49M | -110.57M | 0.00 |
VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-10-24 | Initiated | BofA Securities | Buy |
Dec-20-23 | Initiated | BTIG Research | Buy |
Aug-08-23 | Initiated | Guggenheim | Buy |
Aug-08-23 | Initiated | Jefferies | Buy |
Aug-08-23 | Initiated | Stifel | Buy |
Aug-08-23 | Initiated | TD Cowen | Outperform |
Aug-08-23 | Initiated | Wedbush | Outperform |
View All
Apogee Therapeutics Inc Stock (APGE) Latest News
Victory Capital Management Inc. Boosts Stake in Apogee Therapeutics, Inc. (NASDAQ:APGE) - MarketBeat
Apogee Therapeutics, Inc. (NASDAQ:APGE) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024 - The Manila Times
Apogee Therapeutics Unveils First R&D Day: Spotlight on APG777 and Immunology Pipeline | APGE Stock News - StockTitan
Wedbush Cuts Earnings Estimates for Apogee Therapeutics - MarketBeat
Driehaus Capital Management LLC Acquires Shares in Apogee Therap - GuruFocus.com
Apogee Therapeutics (NASDAQ:APGE) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Stifel maintains Buy on Apogee Therapeutics with $95 target - Investing.com India
FMR LLC Adjusts Stake in Apogee Therapeutics Inc - GuruFocus.com
Apogee Therapeutics Highlights Pipeline Progress and Financials - TipRanks
APGEApogee Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Stifel maintains Buy on Apogee Therapeutics with $95 target By Investing.com - Investing.com UK
Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial Results - GlobeNewswire
Apogee Reports Promising APG777 Trial Data, $754M Cash Runway Through 2028 | APGE Stock News - StockTitan
Apogee Therapeutics Earnings Preview: APG777's Potential In Atopic Dermatitis - Seeking Alpha
Apogee Therapeutics, Inc. (NASDAQ:APGE) Insider Carl Dambkowski Sells 6,665 Shares - MarketBeat
Michael Thomas Henderson Sells 15,000 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) Stock - MarketBeat
Apogee Therapeutics Inc (APGE) Worth Considering For The Next Few Weeks - Stocks Register
Insider Sale at Apogee Therapeutics Inc (APGE): Chief Medical Of - GuruFocus.com
Apogee Therapeutics chief medical officer sells shares worth $394,041 - Investing.com India
Apogee Therapeutics CEO sells shares worth $888,320 - Investing.com
Apogee Therapeutics chief medical officer sells shares worth $394,041 By Investing.com - Investing.com UK
(APGE) Proactive Strategies - Stock Traders Daily
Apogee Therapeutics (NASDAQ:APGE) and Fennec Pharmaceuticals (NASDAQ:FENC) Financial Contrast - Defense World
Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Bought by Mirae Asset Global Investments Co. Ltd. - Defense World
Apogee Therapeutics to Participate in Upcoming November Investor Conferences - GlobeNewswire
Jade, another biotech spinout of Paragon, to merge with Aerovate - BioPharma Dive
10 Best IPO Stocks To Buy Heading into 2025 - Insider Monkey
(APGE) Investment Analysis and Advice - Stock Traders Daily
Apogee Therapeutics, Inc. (NASDAQ:APGE) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Wedbush Reiterates Outperform Rating for Apogee Therapeutics (NASDAQ:APGE) - MarketBeat
Apogee Therapeutics Unveils Promising Phase 1 Trial Results - TipRanks
Apogee Therapeutics Announces Results Up to 9 Months from - GlobeNewswire
Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel - The Bakersfield Californian
Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases - StockTitan
Waypoint Capital Advisors LLC Invests $36.84 Million in Apogee Therapeutics, Inc. (NASDAQ:APGE) - MarketBeat
Apogee Therapeutics (NASDAQ:APGE) Trading Down 4.1%Here's What Happened - MarketBeat
(APGE) Technical Pivots with Risk Controls - Stock Traders Daily
Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting - GlobeNewswire
11,535 Shares in Apogee Therapeutics, Inc. (NASDAQ:APGE) Acquired by AQR Capital Management LLC - MarketBeat
Apogee Therapeutics, Inc. (NASDAQ:APGE) Short Interest Down 11.7% in September - MarketBeat
Millennium Management LLC Lowers Stock Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE) - MarketBeat
Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Sold by The Manufacturers Life Insurance Company - MarketBeat
Analyzing Apogee Therapeutics Inc. (APGE) After Recent Trading Activity - Knox Daily
Ratio Examination: Apogee Therapeutics Inc. (APGE)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Apogee Therapeutics, Inc. (APGE): A Hot Stock to Buy Now - Insider Monkey
Squarepoint Ops LLC Purchases 25,829 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) - MarketBeat
Apogee Therapeutics executive sells over $370k in company stock - Investing.com India
Apogee Therapeutics Inc CEO Michael Henderson Sells 40,000 Shares - GuruFocus.com
Carl Dambkowski Sells 6,665 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) Stock - MarketBeat
Apogee Therapeutics CEO sells over $2.2 million in company stock By Investing.com - Investing.com Canada
Apogee Therapeutics Inc Stock (APGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):